Your browser has either disabled or does not support javascript. Javascript is required for full website experience.
Apellis Pharmaceuticals Inc.
APLS
$
32.8
-1.8%
Mon October 5th, 2020
16:33
Analysis
BioCryst's BCX9930: Alexion's Biggest Headache Now
Seeking Alpha
Wed September 16th, 2020
13:43
Analysis
Apellis Submits Pegcetacoplan Applications to FDA and EMA
Zacks
Tue September 1st, 2020
11:34
Analysis
Apellis Pharmaceuticals started at buy with $40 stock price target at Stifel Nicolaus
MarketWatch
Sun August 30th, 2020
15:30
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
Earnings
Analysis
Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 3.8% Since Last Earnings Report?
Zacks
Thu July 9th, 2020
06:44
Analysis
Apellis Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha
Sun July 5th, 2020
07:31
Analysis
PolyPid Phase 3 And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha
Wed June 24th, 2020
18:50
Analysis
Apellis Pharmaceuticals (APLS) Investor Presentation - Slideshow
Seeking Alpha
Fri June 12th, 2020
16:44
Analysis
Apellis Pharmaceuticals (APLS) PEGASUS Phase 3 Detailed Results Conference Call - Slideshow
Seeking Alpha
Wed June 10th, 2020
18:44
Analysis
Alexion Pharmaceuticals: Patent Resolution Is Too Little Too Late
Seeking Alpha
Fri May 22nd, 2020
15:19
Applied Genetic Reports Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha
